Nanobiotix S.A. NBTX
Nanobiotix S.A. (Nasdaq: NBTX) is an oncology drug developer. Its lead program, JNJ-1900 (NBTXR3), is in Phase 3 for Locally advanced platinum-ineligible head and neck squamous cell cancer (NANORAY-312); also Stage III unresectable NSCLC and recurrent NSCLC.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| JNJ-1900 (NBTXR3) | Head and neck cancer, cisplatin-ineligible (NANORAY-312, global randomized Phase 3, Janssen-sponsored; protocol amended to remove interim analysis) | small molecule | Phase 3 |
| JNJ-1900 (NBTXR3) | Stage III unresectable NSCLC (CONVERGE, Phase 2, J&J-led) | small molecule | Phase 2 |
| JNJ-1900 (NBTXR3) | Locally advanced head and neck cancer (LUMIRAY, Phase 1b, J&J-led) | small molecule | Phase 1 |
| JNJ-1900 (NBTXR3) | Inoperable locoregionally recurrent NSCLC re-irradiation (MD Anderson-sponsored Phase 1; dose-escalation and expansion complete, further enrollment planned) | small molecule | Phase 1 |
| Nanoprimer platform | Extrahepatic delivery of LNP-based therapeutics | unclear | Pre-clinical |
| Neurological disease platform | Neurological conditions | unclear | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.